ENTRADA THERAPEUTICS, INC. Operating Lease Cost
ENTRADA THERAPEUTICS, INC. (TRDA) reported Operating Lease Cost of $15.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- ENTRADA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2023-12-31 was $3.89M, a 69.41% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2023-09-30 was $4.06M, a 77.16% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2023-06-30 was $4.78M, a 108.19% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2023-03-31 was $3.67M, a 93.92% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $15.05M, a 3.12% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $15.54M, a 5.25% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $16.39M, a 86.86% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $8.77M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.05M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $15.54M 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $7.95M derived: sum of 2 quarters · filed 2024-03-13 | $12.73M derived: sum of 3 quarters · filed 2024-03-13 | $16.39M 10-K · filed 2024-03-13 |
| 2023-09-30 | $4.06M 10-Q · filed 2023-11-07 | $8.84M derived: sum of 2 quarters · filed 2023-11-07 | $12.51M 10-Q · filed 2023-11-07 | $14.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $4.78M 10-Q · filed 2023-08-08 | $8.44M 10-Q · filed 2023-08-08 | $10.74M derived: sum of 3 quarters · filed 2023-08-08 | $13.03M derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | $3.67M 10-Q · filed 2023-05-10 | $5.96M derived: sum of 2 quarters · filed 2023-05-10 | $8.25M derived: sum of 3 quarters · filed 2023-05-10 | $10.55M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $4.59M derived: sum of 2 quarters · filed 2023-03-06 | $6.88M derived: sum of 3 quarters · filed 2023-03-06 | $8.77M 10-K · filed 2023-03-06 |
| 2022-09-30 | $2.29M 10-Q · filed 2022-11-07 | $4.59M derived: sum of 2 quarters · filed 2022-11-07 | $6.48M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $2.29M 10-Q · filed 2022-08-11 | $4.18M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $1.89M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |